natgillin/translations-raw huggingface dataset:
The necessary amount of bevacizumab should be withdrawn and diluted to the required administration volume with sodium chloride 9 mg/ml (0.9%) solution for injection. 
Treba izvući potrebnu količinu bevacizumaba i razrijediti je otopinom natrijevog klorida 9 mg/ml
p-value (Chi-squared Test) Kaplan-Meier estimates 
Kaplan-Meierove procjene
In addition, the primary endpoint was also assessed by an independent review committee (IRC). 
Osim toga, primarnu mjeru ishoda ocijenilo je i neovisno ocjenjivačko povjerenstvo.
Bevacizumab in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. 
Bevacizumab je u kombinaciji s kapecitabinom indiciran za prvu liniju liječenja odraslih bolesnika s metastatskim karcinomom dojke za koje se liječenje drugim kemoterapijskim protokolima, uključujući taksane odnosno antracikline, ne smatra primjerenim.
In clinical trials across indications, the overall incidence of venous thromboembolic reactions ranged from 2.8% to 17.3% of Avastin-treated patients compared with 3.2% to 15.6% in the control arms. 
U kliničkim ispitivanjima u svim indikacijama ukupna se incidencija venskih tromboembolijskih reakcija kretala od 2,8% do 17,3% u bolesnika liječenih lijekom Avastin te od 3,2% do 15,6% u kontrolnim skupinama.
• In a retrospective single institution series, 12 consecutive (2005 to 2008) children with relapsed or progressive high-grade glioma (3 with WHO Grade IV, 9 with Grade III) were treated with bevacizumab (10 mg/kg) and irinotecan (125 mg/m²) every 2 weeks. 
Retrospektivnim pregledom u jednoj ustanovi, 12 uzastopno (od 2005. do 2008.) otkrivene djece s relapsirajućim ili progresivnim gliomom visokog stupnja malignosti (3 stupnja IV prema WHO, 9 stupnja III) liječeno je bevacizumabom (10 mg/kg) i irinotekanom (125 mg/m2) svaka 2 tjedna.
The difference in ORR per independent central review was 18% (CI: 0.6%, 35.3%) between the two treatment arms in the few patients who had evaluable tumor at baseline and had a confirmed response prior to receiving any local therapy : 27/75 patients (36.0%, 95% CI: 25.2%, 47.9%) in the Chemo arm and 34/63 patients (54.0%, 95% CI: 40.9%, 66.6%) in the Bv + Chemo arm. 
Prema ocjeni neovisnog središnjeg povjerenstva, razlika u ORR-u između dvije liječene skupine iznosila je 18% (CI: 0,6%, 35,3%) u malobrojnih bolesnika koji su na početku ispitivanja imali tumor koji se mogao ocijeniti te potvrđen odgovor prije nego što su primili bilo koju lokalnu terapiju: 27/75 bolesnika (36,0%; 95% CI: 25,2%, 47,9%) u skupini liječenoj kemoterapijom te 34/63 bolesnika (54,0%; 95% CI: 40,9%, 66,6%) u skupini koja je primala bevacizumab + kemoterapiju.
● Superiority of the Avastin-containing arms versus the chemotherapy alone arms in the overall comparison was demonstrated in terms of progression-free survival in the ITT population (Table 7). 
● Superiornost protokola koji su obuhvaćali Avastin u odnosu na samu kemoterapiju u cjelovitoj je usporedbi dokazana s obzirom na preživljenje bez progresije bolesti u populaciji bolesnika u kojoj je planirano liječenje (ITT populaciji) (Tablica 7).
Keep the vial in the outer carton 
Bočicu čuvati u vanjskom pakiranju
Cerebrovascular accidents (including transient ischaemic attacks) were reported in up to 2.7% of patients treated with Avastin in combination with chemotherapy compared to up to 0.5% of patients treated with chemotherapy alone. 
Cerebrovaskularni incidenti (uključujući i tranzitorne ishemijske atake) prijavljeni su u najviše 2,7% bolesnika liječenih lijekom Avastin u kombinaciji s kemoterapijom u odnosu na najviše 0,5% bolesnika liječenih samo kemoterapijom.
• an open sore or hole in the lining of the stomach or small intestine (the signs may include abdominal pain, feeling bloated, black tarry stools or blood in your stools (faeces) or blood in your vomit), 
● otvorena rana ili napuknuće u stijenci želuca ili tankog crijeva (znakovi mogu biti bol u trbuhu, osjećaj napuhnutosti, crna katranasta stolica ili krv u stolici te krv kod povraćanja),
Caution should be exercised when treating patients with clinically significant cardiovascular disease such as pre-existing coronary artery disease, or congestive heart failure with Avastin. 
Potreban je oprez kad se Avastin primjenjuje u bolesnika s klinički značajnom bolešću srca i krvnih žila, poput postojeće bolesti koronarnih arterija ili kongestivnog zatajenja srca.
Of the 452 patients randomized at baseline, the majority of patients were white (80.0% in the Chemo alone group and 75.3% in the Chemo+Avastin group), had squamous cell carcinoma (67.1% in the Chemo alone group and 69.6% in the Chemo+Avastin group), had persistent/recurrent disease (83.6% in the Chemo alone group and 82.8% in the Chemo+Avastin group), had 1-2 metastatic sites (72.0% in the Chemo alone group and 76.2% in the Chemo+Avastin group), had lymph node involvement (50.2% in the Chemo alone group and 56.4% in the Chemo+Avastin group), and had a platinum free interval ≥ 6 months (72.5% in the Chemo alone group and 64.4% in the Chemo+Avastin group). 
Od 452 bolesnice randomizirane na početku ispitivanja većina su bile bjelkinje (80,0% u skupini koja je primala samo kemoterapiju i 75,3% u skupini koja je primala kemoterapiju+Avastin) te su većinom imale planocelularni karcinom (67,1% u skupini koja je primala samo kemoterapiju i 69,6% u skupini koja je primala kemoterapiju+Avastin), perzistentnu/recidivirajuću bolest (83,6% u skupini koja je primala samo kemoterapiju i 82,8% u skupini koja je primala kemoterapiju+Avastin), 1 do 2 metastatska sijela (72,0% u skupini koja je primala samo kemoterapiju i 76,2% u skupini koja je primala kemoterapiju+Avastin), zahvaćene limfne čvorove (50,2% u skupini koja je primala samo kemoterapiju i 56,4% u skupini koja je primala kemoterapiju+Avastin) i interval bez liječenja platinom ≥ 6 mjeseci (72,5% u skupini koja je primala samo kemoterapiju i 64,4% u skupini koja je primala kemoterapiju+Avastin).
Progression-free survival and objective response rate were inferior in the Avastin monotherapy arm compared to the FOLFOX-4 arm. 
Preživljenje bez progresije bolesti i stopa objektivnog odgovora bili su lošiji u skupini koja je primala Avastin u monoterapiji nego u skupini liječenoj protokolom FOLFOX-4.
Combination of bevacizumab and sunitinib malate In two clinical trials of metastatic renal cell carcinoma, microangiopathic haemolytic anaemia (MAHA) was reported in 7 of 19 patients treated with bevacizumab (10 mg/kg every two weeks) and sunitinib malate (50 mg daily) combination. 
U dva klinička ispitivanja metastatskog karcinoma bubrežnih stanica u 7 od 19 bolesnika liječenih kombinacijom bevacizumaba (10 mg/kg svaka dva tjedna) i sunitinib malata (50 mg dnevno)
Bevacizumab, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see Section 5.1). 
Bevacizumab je u kombinaciji s paklitakselom i cisplatinom ili, alternativno, paklitakselom i topotekanom u bolesnica koje ne mogu primiti terapiju platinom, indiciran za liječenje odraslih bolesnica s perzistentnim, recidivirajućim ili metastatskim karcinomom cerviksa (vidjeti dio 5.1).
If you have conditions causing inflammation inside the abdomen (e.g. diverticulitis, stomach ulcers, colitis associated with chemotherapy), please discuss this with your doctor. 
Ako bolujete od stanja koja uzrokuju upale u trbuhu (npr. divertikulitis, želučani vrijed, kolitis povezan s kemoterapijom),
Hypersensitivity, infusion reactionsa,b,d 
Poremećaji imunološkog sustava preosjetljivost, infuzijske reakcijea,b,d
Gall bladder perforation (not known) 
Perforacija nosnog septuma (nepoznato)
Bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations (see Section 5.1). 
Bevacizumab je u kombinaciji s erlotinibom indiciran za prvu liniju liječenja odraslih bolesnika s neresektabilnim uznapredovalim, metastatskim ili recidivirajućim neskvamoznim karcinomom pluća nemalih stanica s aktivirajućim mutacijama receptora epidermalnog faktora rasta (engl. epidermal growth factor receptor, EGFR) (vidjeti dio 5.1).
Uncommon (≥ 0.1% to < 1%) reports of fistulae that involve areas of the body other than the gastrointestinal tract (e.g. bronchopleural and biliary fistulae) were observed across various indications. 
U ispitivanjima u raznim indikacijama manje često (≥ 0,1% i < 1%) su prijavljene fistule u dijelovima tijela izvan gastrointestinalnog trakta (npr. bronhopleuralne i bilijarne fistule).
Proteinuria ranged in severity from clinically asymptomatic, transient, trace proteinuria to nephrotic syndrome, with the great majority as Grade 1 proteinuria (NCI-CTCAE v.3). 
Težina proteinurije kretala se od klinički asimptomatske, kratkotrajne proteinurije u tragovima do nefrotskog sindroma, no u najvećem broju slučajeva radilo se o proteinuriji stupnja 1 (NCI-CTCAE v.3).
Venous thromboembolism: The incidence of venous thromboembolic reactions in clinical trials was similar in patients receiving Avastin in combination with chemotherapy compared to those receiving the control chemotherapy alone. 
Venska tromboembolija: Incidencija venskih tromboembolijskih reakcija u kliničkim ispitivanjima bila je slična u bolesnika koji su primali Avastin u kombinaciji s kemoterapijom i bolesnika u kontrolnoj skupini koji su primali samo kemoterapiju.
The percentage of patients with an ECOG PS of 1 or ≥ 2 was 38.7% and 5.0% in the CT arm, and 29.8% and 9.0% in the 
Postotak bolesnica s ECOG funkcionalnim statusom 1 odnosno ≥ 2 iznosio je 38,7% odnosno 5,0% u skupini koja je primala KT te 29,8% odnosno 9,0% u skupini koja je primala KT+BV.
Oxaliplatin 130 mg/m2 IV 2 h Oxaliplatin on day 1 Capecitabine oral bid for 2 weeks (followed by 1 week off treatment) 
130 mg/m i.v. 2 h oksaliplatin 1. dana kapecitabin, peroralno, dva puta na dan tijekom 2 tjedna (slijedi jednotjedni prekid)
Frequency Not Known 
Nepoznata učestalost
Most of the patients who experienced CHF had metastatic breast cancer and had received previous treatment with anthracyclines, prior radiotherapy to the left chest wall or other risk factors for CHF were present. 
Većina bolesnika s kongestivnim zatajenjem srca imala je metastatski karcinom dojke te su prethodno liječeni antraciklinima, radioterapijom lijeve strane prsnog koša ili su pak postojali drugi čimbenici rizika za kongestivno zatajenje srca.
This was a phase II randomised, double-blind, active-controlled clinical trial evaluating the efficacy and safety of Avastin in combination with 5-FU/FA as first-line treatment for metastatic colorectal cancer in patients who were not optimal candidates for first-line irinotecan treatment. 
Riječ je o randomiziranom, dvostruko slijepom, aktivno kontroliranom kliničkom ispitivanju faze II, u kojemu se određivala djelotvornost i sigurnost primjene lijeka Avastin u kombinaciji s protokolom 5-FU/FA kao prve linije liječenja metastatskog kolorektalnog karcinoma u bolesnika koji nisu bili optimalni kandidati za primjenu irinotekana u prvoj liniji liječenja.
Investigator assessed GOG protocol-specified PFS analysis (neither censored for CA-125 progressions nor censored for NPT prior to disease progression) with data cut-off date of 25 February, 2010. 
Analiza preživljenja bez progresije bolesti po procjeni ispitivača sukladno protokolu GOG (nije cenzurirana za porast razine CA-125 ni za terapiju izvan protokola prije progresije bolesti), prema podacima do 25. veljače 2010.
In clinical trials across all indications the overall incidence of NCI-CTCAE v.3 Grade 3-5 bleeding reactions ranged from 0.4% to 6.9% in Avastin treated patients, compared with up to 4.5% of patients in the chemotherapy control group. 
U kliničkim ispitivanjima u svim indikacijama ukupna incidencija reakcija krvarenja stupnja 3-5 prema NCI-CTCAE iznosila je od 0,4% do 6,9% u bolesnika liječenih lijekom Avastin u odnosu na najviše 4,5% u bolesnika u kontrolnoj skupini liječenoj kemoterapijom.
Patients with NSCLC of known squamous cell histology or mixed cell type with predominant squamous cell histology were excluded from subsequent phase III trials, while patients with unknown tumour histology were included. 
mješovitog staničnog tipa s prevladavajućom histologijom skvamoznih stanica nisu bili uključeni u daljnja ispitivanja faze III, dok su bolesnici s tumorom nepoznate histologije bili uključeni.
A third group of 110 patients received bolus 5-FU/FA + Avastin (Arm 3). 
Treća skupina sa 110 bolesnika primala je bolus 5FU/FA
The choices of chemotherapy included capecitabine, taxane (protein-bound paclitaxel, docetaxel), and anthracycline-based agents (doxorubicin/ cyclophosphamide, epirubicin/ cyclophosphamide, 5-fluorouracil/ doxorubicin/ cyclophosphamide, 5-fluorouracil/epirubicin/cyclophosphamide) given every three weeks (q3w). 
taksan (paklitaksel vezan za proteine, docetaksel) i lijekove na bazi antraciklina (doksorubicin/ciklofosfamid, epirubicin/ciklofosfamid, 5-fluorouracil/doksorubicin/ciklofosfamid, 5-fluorouracil/epirubicin/ciklofosfamid) koji su davani svaka tri tjedna.
Table 2: Severe Adverse Reactions by Frequency System organ class 
Tablica 2: Teške nuspojave prema učestalosti
Other reactions with a higher frequency seen in patients over 65 were Grade 3-4 leucopenia and thrombocytopenia (NCI-CTCAE v.3); and all Grade neutropenia, diarrhoea, nausea, headache and fatigue as compared to those aged ≤ 65 years when treated with Avastin (see sections 4.4 and 4.8 under Thromboembolism). 
Avastin zabilježene češće u bolesnika starijih od 65 godina u usporedbi s bolesnicima u dobi od ≤ 65 godina bile su leukopenija i trombocitopenija stupnja 3-4 (NCI-CTCAE v.3) te neutropenija, proljev, mučnina, glavobolja i umor bilo kojeg stupnja (vidjeti dijelove 4.4 i 4.8, pod
Proteinuriab,d 
hemoptizab,d,
• Study AVF3694g (capecitabine) • Median PFS increase 2.9 months, HR 0.69 (p = 0.0002, 95% CI 0.56; 0.84) 
• Medijan produljenja preživljenja bez progresije bolesti: 2,9 mjeseci, HR = 0,69 (p = 0,0002; 95% CI = 0,56; 0,84)
In study BO20924 of Avastin with current standard of care in rhabdomyosarcoma and nonrhabdomyosarcoma soft tissue sarcoma, the safety profile of Avastin treated children was comparable with that observed in adults treated with Avastin. 
U ispitivanju BO20924, u kojem se ispitivao Avastin s trenutnom standardnom terapijom u liječenju metastatskog rabdomiosarkoma i sarkoma mekog tkiva koji nije rabdomiosarkom, sigurnosni profil lijeka u djece liječene lijekom Avastin bio je usporediv s onim primijećenim u odraslih osoba liječenih lijekom Avastin.
Gastrointestinal ulcera 
proktalgija gastrointestinalni ulkusa
The HR for PFS was 0.47 (95% CI: 0.35, 0.62) and 0.45 (95% CI: 0.31, 0.67) for the < 65 and ≥ 65 subgroups, respectively. 
Omjer hazarda za preživljenje bez progresije bolesti iznosio je 0,47 (95% CI: 0,35; 0,62) za podskupinu bolesnica mlađih od 65 godina, odnosno 0,45 (95% CI: 0,31; 0,67) za podskupinu u dobi od ≥ 65 godina.
If this is well-tolerated the second infusion may be given over 60 minutes. 
Ako je dobro podnesete, druga infuzija može trajati 60 minuta.
• inflammation of the moist lining of mouth and gut, lungs and air passages, reproductive, and urinary tracts, 
● upalu sluznice usta i crijeva, pluća i dišnih putova, spolnog i mokraćnog sustava,
The risk of Avastin-associated hypertension did not correlate with the patients' baseline characteristics, underlying disease or concomitant therapy. 
Rizik od hipertenzije vezane uz Avastin nije bio u korelaciji s bolesnikovim karakteristikama na početku liječenja, bolešću koja se liječi ili popratnom terapijom.
During the blinded treatment phase, patients received chemotherapy and medicinal product (Avastin or placebo) every 3 weeks until disease progression, treatment-limiting toxicity, or death. 
Tijekom slijepe faze liječenja bolesnici su primali kemoterapiju i lijek (Avastin odnosno placebo) svaka 3 tjedna do nastupa progresije bolesti,
Enrolment in Arm 3 was discontinued, as pre-specified, once safety of Avastin with the IFL regimen was established and considered acceptable. 
Prema planu ispitivanja uključivanje u treću skupinu prekinuto je čim je utvrđena i prihvatljivom ocijenjena sigurnost primjene lijeka Avastin u kombinaciji s protokolom IFL.
Secondary efficacy endpoints included progression-free survival and objective response rate. 
Sekundarne mjere ishoda uključivale su preživljenje bez progresije bolesti i stopu objektivnog odgovora.
Cap + Avastin (n=325) 
Kap + Avastin (n= 325)
You could also experience redness or flushing of the skin or a rash, chills and shivering, feeling sick (nausea) or being sick (vomiting). 
Također se mogu javiti crvenilo ili crvenilo uz osjećaj vrućine ili osip kože, zimica i tresavica, mučnina ili povraćanje.
Avastin therapy should be discontinued in patients who develop necrotising fasciitis, and appropriate treatment should be promptly initiated. 
U bolesnika u kojih se razvije nekrotizirajući fasciitis terapiju lijekom Avastin treba prekinuti i odmah započeti s odgovarajućim liječenjem.
When used for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer, it will be administered in combination with carboplatin and paclitaxel. 
Kada se koristi za bolesnice s uznapredovalim epitelnim rakom jajnika, rakom jajovoda ili primarnim peritonealnim rakom, primjenjuje se u kombinaciji s karboplatinom i paklitakselom.
Patients treated with Avastin have an increased risk of haemorrhage, especially tumour-associated haemorrhage. 
Bolesnici liječeni lijekom Avastin izloženi su povećanom riziku od krvarenja, a osobito krvarenja povezanog s tumorom.
Cases of ONJ have been reported in cancer patients treated with Avastin, the majority of whom had received prior or concomitant treatment with intravenous bisphosphonates, for which ONJ is an identified risk. 
Prijavljeni su slučajevi osteonekroze čeljusti u bolesnika s malignom bolešću liječenih lijekom Avastin, od kojih je većina prethodno ili istodobno primala intravenske bisfosfonate, kod čije primjene osteonekroza čeljusti predstavlja poznat rizik.
need to be closely monitored (NCI-CTCAE v.3). 
(NCI-CTCAE v.3).
Seventy-one patients were randomised to receive bolus 5-FU/FA or 5-FU/FA + Avastin (5 mg/kg every 2 weeks). 
Randomiziran je 71 bolesnik, ili za bolus 5-FU/FA ili za 5-FU/FA + Avastin (5 mg/kg svaka 2 tjedna).
If the first infusion is well tolerated, the second infusion may be administered over 60 minutes. 
Ako bolesnik dobro podnese prvu infuziju, drugu je moguće primijeniti tijekom 60 minuta.
Oxaliplatin 85 mg/m2 IV 2 h Oxaliplatin on day 1 Leucovorin on day 1 and 2 
85 mg/m i.v. 2 h oksaliplatin 1. dana leukovorin 1. i 2. dana 5-fluorouracil i.v. bolus/infuzija, oboje 1. i 2. dana leukovorin
In a randomized phase II study (BO25041) a total of 121 patients aged ≥ 3 years to <18 years with newly diagnosed supratentorial or infratentorial cerebellar or peduncular high-grade glioma (HGG) were treated with post operative radiation therapy (RT) and adjuvant temozolomide (T) with and without bevacizumab: 10 mg/kg every 2 weeks IV. 
U randomiziranom ispitivanju faze II (BO25041) ukupno je 121 bolesnik u dobi od ≥ 3 godine do < 18 godina s novodijagnosticiranim supratentorijalnim ili infratentorijalnim cerebelarnim ili pedunkularnim gliomom visokog stupnja bio liječen poslijeoperacijskom radioterapijom (RT) i adjuvantnim temozolomidom (T) u kombinaciji s bevacizumabom i bez njega: 10 mg/kg svaka 2 tjedna intravenski.
Final overall survival analysis performed when 46.9% of the patients had died. 
Bolesnice s mjerljivom bolešću na početku ispitivanja Finalna analiza ukupnog preživljenja izvršena je nakon što je umrlo 46,9% bolesnica.
● serious infections of the skin or deeper layers under the skin, 
● u slučaju ozbiljne infekcije kože ili dubljih potkožnih slojeva
● Keep this leaflet. 
Sačuvajte ovu uputu.
Gastrointestinal disorders 
gastrointestinalni poremećaj,
This study was designed as an open-label, randomized, two-arm Phase III evaluation of bevacizumab plus chemotherapy (CT+BV) versus chemotherapy alone (CT). 
Ispitivanje je osmišljeno kao otvoreno, randomizirano ispitivanje faze III u dvije skupine, u kojem se ocjenjivala primjena bevacizumaba i kemoterapije (KT+BV) naspram primjene samo kemoterapije (KT).
Bevacizumab in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. 
Bevacizumab je u kombinaciji s kemoterapijom na bazi fluoropirimidina indiciran za liječenje odraslih bolesnika s metastatskim karcinomom kolona ili rektuma.
Bevacizumab in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. 
Bevacizumab je u kombinaciji s interferonom alfa-2a indiciran za prvu liniju liječenja odraslih bolesnika s uznapredovalim i/ili metastatskim karcinomom bubrežnih stanica.
5.0 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks 
a 5,0 mg/kg svaka 2 tjedna ili 7,5 mg/kg svaka 3 tjedna
Overall response rate Rate (percent) 95% CI p-value 
Ukupna stopa odgovora Stopa (postotak) 95% CI p-vrijednost
Treatment was given until progressive disease or unacceptable toxicity. 
Liječenje se nastavilo do progresije bolesti ili do pojave neprihvatljive toksičnosti.
The primary endpoint of this trial was progression free survival (PFS), based on trial investigators' assessment of disease progression. 
Primarna mjera ishoda ovog ispitivanja bilo je preživljenje bez progresije bolesti, na temelju ispitivačeve procjene progresije bolesti.
In clinical trials with Avastin, congestive heart failure (CHF) was observed in all cancer indications studied to date, but occurred predominantly in patients with metastatic breast cancer. 
U kliničkim ispitivanjima lijeka Avastin kongestivno zatajenje srca zabilježeno je u svim dosad ispitivanim onkološkim indikacijama, no najčešće se javljalo u bolesnika s metastatskim rakom dojke.
An independent review of the primary endpoint was also conducted. 
Provedena je i neovisna procjena primarne mjere ishoda.
Results from the randomised phase III studies, PACCE and CAIRO-2, in patients with mCRC suggest that the use of anti-EGFR monoclonal antibodies panitumumab and cetuximab, respectively, in combination with bevacizumab plus chemotherapy, is associated with decreased PFS and/or OS, and with increased toxicity compared with bevacizumab plus chemotherapy alone. 
Rezultati randomiziranih ispitivanja faze III PACCE i CAIRO-2 u bolesnika s metastatskim karcinomom kolona ili rektuma ukazuju na to da je primjena monoklonskih protutijela protiv EGFR-a, panitumumaba i cetuksimaba, u kombinaciji s kemoterapijom i bevacizumabom povezana s kraćim preživljenjem bez progresije bolesti i/ili ukupnim preživljenjem te s povećanom toksičnošću u usporedbi s primjenom samo bevacizumaba i kemoterapije.
The trial contained two parts: an initial unblinded 2-arm part (Part I) in which patients were randomised to two different treatment groups (XELOX and FOLFOX-4) and a subsequent 2 x 2 factorial 4-arm part (Part II) in which patients were randomised to four treatment groups (XELOX + placebo, FOLFOX-4 + placebo, XELOX + Avastin, FOLFOX-4 + Avastin). 
U sljedećem dijelu (dio II) sastavljenom od 4 skupine prema faktorijalnom nacrtu 2 x 2 bolesnici su randomizirani u četiri terapijske skupine (XELOX + placebo, FOLFOX-4 + placebo, XELOX +
● a blood clot in your arteries, 
● u slučaju krvnog ugruška u arterijama,